Advertisement

Clinical Rheumatology

, Volume 31, Issue 7, pp 1079–1086 | Cite as

A randomized, single-blind comparison of the efficacy and tolerability of hyaluronate acid and meloxicam in adult patients with Kashin–Beck disease of the knee

  • Xin Tang
  • Fu-Xing PeiEmail author
  • Zong-Ke Zhou
  • Gang Liu
  • Bin Shen
  • Peng-De Kang
  • Jian Li
  • Xiao-Dan Zhao
  • Qi Li
  • Yong Li
Original Article

Abstract

The aim of this study was to prospectively evaluate the efficacy and tolerability of hyaluronic acid (HA) and meloxicam for the treatment of knee pain due to Kashin–Beck disease (KBD). A total of 162 patients with KBD-based knee pain were randomly assigned to treatment with a 3-week course of HA (n = 80) and a 12-week course of meloxicam (n = 82). Clinical assessments for each patient were made at 0 (baseline), 1, 2, 4, 8, and 12 weeks. The primary efficacy measure was visual analog scale (VAS) pain score. Second efficacy measures comprised the Western Ontario and McMaster Universities (WOMAC) A (pain), B (stiffness), and C (function) scores as well as patients’ and physicians’ global assessments. Tolerability was evaluated based on adverse events (AEs) and physician reporting. The VAS rapidly decreased in both groups over 12 weeks. The VAS improvement observed in HA group was lower at week 1 (p = 0.001) but better at weeks 8 and 12 (p < 0.001) than the meloxicam group, which were supported by the secondary variables of WOMAC A (p = 0.001) and WOMAC C (p < 0.001) scores and the global assessments of the patients and their physicians (p = 0.020 and 0.003, respectively). No serious AEs were reported, and the overall incidence of AEs among patients treated with meloxicam was higher than in patients treated with HA (p = 0.012). This study suggests that intra-articular injection of HA and administration of oral meloxicam should be efficacious and well tolerated in the treatment of knee pain due to KBD; the onset of action of meloxicam was faster than that of HA, whereas HA therapy resulted in a more prolonged increasing improvement of symptoms than meloxicam. In addition, HA treatment was likely superior to meloxicam with respect to tolerability. Other randomized double-blind studies are needed to confirm the findings of our open-label study.

Keywords

Hyaluronic acid Kashin–Beck disease Knee Meloxicam 

Notes

Acknowledgments

This research was funded by the China National Science & Technology Pillar Program during the eleventh 5-year plan period (2007BAI 25B04). The authors would like to thank Local Village Committee in Rangtang County for support and cooperation in the collection of data. The authors also thank the following for their contributions to study design and manuscript preparation: Jing Yang (study conception and design), Yong-tao Cheng (study conception), and Cheng-pei Zhou (AE review).

Disclosures

The authors report no competing interests.

References

  1. 1.
    Sokoloff L (1989) The history of Kashin–Beck disease. N Y State J Med 89:343–351PubMedGoogle Scholar
  2. 2.
  3. 3.
    Schepman K, Engelbert RH, Visser MM, Yu C, de Vos R (2011) Kashin Beck disease: more than just osteoarthrosis: a cross-sectional study regarding the influence of body function–structures and activities on level of participation. Int Orthop 35:767–776PubMedCrossRefGoogle Scholar
  4. 4.
    Guo X (2001) Diagnostic, clinical and radiological characteristics of Kashin–Beck disease in Shaanxi Province, PR China. Int Orthop 25:147–150CrossRefGoogle Scholar
  5. 5.
    Cao J, Li S, Shi Z, Yue Y, Sun J, Chen J et al (2008) Articular cartilage metabolism in patients with Kashin–Beck disease: an endemic osteoarthropathy in China. Osteoarthr Cartil 16:680–688PubMedCrossRefGoogle Scholar
  6. 6.
    Zhou Z, Shen B, Pei F, Kang P, Li J, Yang J et al (2009) Relation between affected big joints and classification of Kashin–Beck disease in adult of Tibet. Chinese J Bone Joint Surgery 2:352–356Google Scholar
  7. 7.
    Luo R, Liu G, Liu W, Pei F, Zhou Z, Li J et al (2011) Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin–Beck disease (KBD) patients. Int Orthop 35:1409–1414PubMedCrossRefGoogle Scholar
  8. 8.
    Bjordal JM, Ljunggren AE, Klovning A, Slørdal L (2004) Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 329:1317PubMedCrossRefGoogle Scholar
  9. 9.
    Mathieu F, Suetens C, Begaux F, De Maertelaer V, Hinsenkamp M (2001) Effects of physical therapy on patients with Kashin–Beck disease in Tibet. Int Orthop 5:191–193Google Scholar
  10. 10.
    Bannuru RR, Natov NS, Dasi UR, Schmid CH, McAlindon TE (2011) Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis—meta-analysis. Osteoarthr Cartil 19:611–619PubMedCrossRefGoogle Scholar
  11. 11.
    Wang CT, Lin J, Chang CJ, Lin YT, Hou SM (2004) Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J Bone Joint Surg Am 86-A:538–545PubMedGoogle Scholar
  12. 12.
    Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G (2006) Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 19:CD005321Google Scholar
  13. 13.
    Xu P, Guo X, Jin W, Yao J, Wang J, Zhang F et al (2004) Curative effects of intra-articular injections of sodium hyaluronate to treat Kashin–Beck disease. Chin J End 23:588–590Google Scholar
  14. 14.
    Chen Y, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G et al (2008) Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 12:1–278, iiiPubMedGoogle Scholar
  15. 15.
    Wojtulewski JA, Schattenkirchner M, Barceló P, Le Loët X, Bevis PJ, Bluhmki E et al (1996) A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 35(Suppl 1):22–28PubMedCrossRefGoogle Scholar
  16. 16.
    Barner A (1996) Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol Suppl 102:29–37PubMedCrossRefGoogle Scholar
  17. 17.
    Li F, Deng J, Zhou D, Yang R, Li D, Ma G et al (2005) Analysis on monitoring data of Kashin–Beck disease in Sichuan Province in 2005. J Prev Med Inform 21:666–668Google Scholar
  18. 18.
    Mathieu F, Begaux F, Lan ZY, Suetens C, Hinsenkamp M (1997) Clinical manifestations of Kashin–Beck disease in Nyemo Valley, Tibet. Int Orthop 21:151–156PubMedCrossRefGoogle Scholar
  19. 19.
    Kellgren JH, Lawrence JS (1957) Radiographic assessment of osteoarthritis. Ann Rheum Dis 16:494–502PubMedCrossRefGoogle Scholar
  20. 20.
    Bellamy N (1995) WOMAC Osteoarthritis Index—a user’s guide. London Health Sciences Centre, LondonGoogle Scholar
  21. 21.
    Bellamy N (2002) WOMAC: a 20-year experiential review of a patient-centered self-reported health status questionnaire. J Rheumatol 29:2473–2476PubMedGoogle Scholar
  22. 22.
    Altman RD, Moskowitz R (1998) Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol 25:2203–2212PubMedGoogle Scholar
  23. 23.
    Dickson DJ, Hosie G, English JR (2001) A double-blind, placebo-controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis. J Drug Assess 4:179–190Google Scholar
  24. 24.
    Adams ME, Atkinson MH, Lussier AJ, Schulz JI, Siminovitch KA, Wade JP et al (1995) The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthr Cartil 3:213–225PubMedCrossRefGoogle Scholar
  25. 25.
    Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M (2008) The placebo effect and its determinants in osteoarthritis: meta-analysis of randomized controlled trials. Ann Rheum Dis 67:1716–1723PubMedCrossRefGoogle Scholar
  26. 26.
    Juni P, Altman DG, Egger M (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323:42–46PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2012

Authors and Affiliations

  • Xin Tang
    • 1
  • Fu-Xing Pei
    • 1
    Email author
  • Zong-Ke Zhou
    • 1
  • Gang Liu
    • 2
  • Bin Shen
    • 1
  • Peng-De Kang
    • 1
  • Jian Li
    • 1
  • Xiao-Dan Zhao
    • 1
  • Qi Li
    • 1
  • Yong Li
    • 1
  1. 1.Department of Orthopaedic surgeryWest China Hospital of Sichuan UniversityChengduPeople’s Republic of China
  2. 2.Department of Immunology and RheumatologyWest China Hospital of Sichuan UniversityChengduPeople’s Republic of China

Personalised recommendations